To Observe The Clinical Study On The Treatment Of Malignant Pleural Effusion Of Advanced Non-Small Cell Lung Cancer With Different Administration Methods Of Endostar

Objective: To observe the efficacy and safety of Endostatin in the treatment of advanced non-small cell lung cancer(NSCLC)complicated with malignant pleural effusion.Methods:From January 2020 to August 2022,according to the inclusion and exclusion criteria,60 patients with advanced NSCLC complicated with malignant pleural effusion of medium or above volume were enrolled in the second Department of Intrapulmonary Cancer Hospital Affiliated to Xinjiang Medical University,and were divided into 28 patients in the thoracic group and 32 patients in the venous group according to random number table.Thoracic administration group was given Intrapulmonary Endostar 45 mg intrathoracic injection,3 times a week,one course of treatment a week for 2 weeks.In the intravenous administration group,Endostar 210 mg micro-infusion pump was used for intravenous drip,every 3 weeks for a course of treatment,for 2 consecutive courses of treatment.After 2 courses of treatment,the short-term efficacy,long-term efficacy,changes in quality of life and adverse reactions were compared between the two groups.Results: The comparison of the short-term efficacy of the two groups showed that the effective rate of the thoracic administration group was 64.3%,and that of the intravenous administration group was 34.4%.The thoracic administration group was significantly better than the intravenous administration group(P < 0.05).The median PFS of the whole group was 4.6 months.The median PFS of the thoracic administration group was 4.9 months,and that of the intravenous administration group was 4.5 months,P > 0.05,and the difference was not statistically significant.In terms of quality of life improvement,there was no significant difference in scores between the two groups before treatment(P > 0.05).After treatment,the thoracic administration group had no statistical significance in physiological status,social/family status and emotional status compared with the intravenous administration group(P > 0.05),while the functional status and lung cancer specific modules of the thoracic administration group were significantly higher than those of the intravenous administration group(P <0.05).After treatment,all scores of the two groups were higher than before treatment,and the difference was statistically significant(P < 0.05).Side effects: A total of 48 patients had 120 adverse events(AE),including 52(43.3%)of 25 patients in the thoracic administration group and 68(56.7%)of 23 patients in the intravenous administration group.Treatment-related adverse events included sinus tachycardia,nausea and vomiting,diarrhea,leukopenia,anemia,elevated alanine aminotransferase,elevated aspartate aminotransferase,rash,hypertension,and fatigue.Most of the adverse reactions were grade 1-2,and there were 3 cases above grade 3,all of which were leukopenia.All of the adverse reactions could be relieved after rest and symptomatic treatment.There was no significant difference in common adverse reactions between the two groups(P >0.05).Conclusions:(1)Endostatin intrathoracic administration in the treatment of lung cancer with MPE may have better short-term efficacy than traditional continuous intravenous pump administration.(2)Endostatin pleural administration and traditional continuous intravenous pump administration can improve the quality of life of patients with lung cancer and MPE,and Endostatin pleural administration is significantly superior to traditional continuous intravenous pump administration in terms of functional status and lung cancer-specific modules.(3)Endostatin intrathoracic administration has no increase in toxicity and side effects compared with continuous intravenous pump administration,and the safety is within a controllable range.